Research and Markets (http://www.researchandmarkets.com/reports/c91788) has announced the addition of “European Markets for Fibromyalgia Syndrome” to their offering.

This research explores the market for therapeutics that are developed for the treatment of Fibromyalgia Syndrome in Europe. It analyses the various challenges faced by the pharmaceutical companies and the competitive advantage of their products in the market.

Key Discussions:

RESEARCH METHODOLOGY

– Research Objective and Scope

Methodology

MARKET OVERVIEW

– Introduction

Disease Characteristics

Epidimeology

– Market Definition and Segmentation

Definition

Segmentation

INDUSTRY CHALLENGES

– Key Challenges

Challenges Faced by the Niche CNS Disorders Markets

TOTAL EUROPEAN MARKETS FOR FIBROMYALGIA SYNDROME

– Overview and Definitions

Market Drivers

Market Restraints

Explored Treatment Options

Unmet Needs

Market Engineering Measurements

– Competitive Analysis

Pfizer

Eli Lilly

Forest/Cypress Bioscience

TOTAL FORECASTS FOR THE EUROPEAN MARKETS FOR FIBROMYALGIA SYNDROME

– Patient and Revenue Forecasts

Patient Population

Revenue Forecasts

STRATEGIC RECOMMENDATIONS

– Recommendations for the European Markets for Fibromyalgia Syndrome.

Recommendations

DATABASE OF KEY INDUSTRY PARTICIPANTS

– Key Market Participants

Companies in the Fibromyalgia Syndrome Market

DECISION SUPPORT DATABASES

– Databases for Analysis

Total Cases of Stroke

Deaths due to Stroke

Total Cases of Epilepsy

Total Cases of Multiple Sclerosis

Deaths due to Epilepsy

Deaths due to Multiple Sclerosis

Companies mentioned:

– Eli Lilly

– Forest/Cypress Bioscience

– Pfizer

For more information visit http://www.researchandmarkets.com/reports/c91788

Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Comments

comments